{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:24:45Z","timestamp":1774031085531,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213160","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T17:32:36Z","timestamp":1552325556000},"page":"e0213160","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV na\u00efve patients: A path analysis approach"],"prefix":"10.1371","volume":"14","author":[{"given":"Carlo","family":"Mengoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Andreis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Scaggiante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ferretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Panese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicio","family":"Manfrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Schiaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Maffongelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Palu'","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8865-5460","authenticated-orcid":true,"given":"Saverio Giuseppe","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel","volume":"316","author":"H G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"ref2","unstructured":"European AIDS Clinical Society Guidelines, Version 8.2\u2014January 2017 http:\/\/www.eacsociety.org<\/ext-link>. Cited 12 June 2017"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e105853","DOI":"10.1371\/journal.pone.0105853","article-title":"A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-na\u00efve patients starting a first-line HAART","volume":"9","author":"D Armenia","year":"2014","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/infdis\/jir218","article-title":"Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy","volume":"204","author":"E Secl\u00e9n","year":"2011","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/jac\/dkw348","article-title":"Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy","volume":"72","author":"C Mengoli","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results","volume":"63","author":"A Zolopa","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial","volume":"201","author":"AR Zolopa","year":"2010","journal-title":"J Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QCO.0000000000000327","article-title":"How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use","volume":"30","author":"E Elliot","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3389\/fmicb.2016.02165","article-title":"Different Pathways Leading to Integrase Inhibitors Resistance","volume":"7","author":"E Thierry","year":"2017","journal-title":"Front Microbiol"},{"key":"ref10","first-page":"3","article-title":"Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015","volume":"39","author":"A Antinori","year":"2016","journal-title":"New Microbiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1128\/JCM.02564-10","article-title":"HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects","volume":"49","author":"SG Parisi","year":"2011","journal-title":"J Clin Microbiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e0177033","DOI":"10.1371\/journal.pone.0177033","article-title":"Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors","volume":"12","author":"T Hayashida","year":"2017","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","article-title":"European guidelines on the clinical management of HIV-1 tropism testing","volume":"11","author":"LP Vandekerckhove","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nbt1371","article-title":"Bioinformatics prediction of HIV coreceptor usage","volume":"25","author":"T Lengauer","year":"2007","journal-title":"Nat Biotechnol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"ref16","first-page":"3172","article-title":"Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression","volume":"72","author":"V Supervie","year":"2017","journal-title":"J Antimicrob Chemother 2017 J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1097\/QAD.0000000000001573","article-title":"Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation","volume":"31","author":"JS Lee","year":"2017","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/QAI.0b013e3181989a8b","article-title":"Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection","volume":"50","author":"MB Goetz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"ref19","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1479-5876-9-S1-S5","article-title":"Clinical significance of HIV-1 coreceptor usage","volume":"9","author":"H Schuitemaker","year":"2011","journal-title":"J Transl Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/09540121.2016.1234678","article-title":"Understanding the delay in starting antiretroviral therapy despite recent guidelines for HIV patients retained in care","volume":"29","author":"N Hoehn","year":"2017","journal-title":"AIDS Care"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s15010-016-0887-x","article-title":"Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape","volume":"44","author":"J Fehr","year":"2016","journal-title":"Infection"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/QAD.0000000000000977","article-title":"Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy","volume":"30","author":"G Maffongelli","year":"2016","journal-title":"AIDS"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/1469-0691.12100","article-title":"Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database","volume":"19","author":"S Rusconi","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"F Raffi","year":"2013","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP2093","article-title":"Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients","volume":"17","author":"JP Bastard","year":"2012","journal-title":"Antivir Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcv.2009.09.011","article-title":"Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies\/ml HIV-1 RNA","volume":"46","author":"S Baroncelli","year":"2009","journal-title":"J Clin Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1471-2334-13-314","article-title":"A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated na\u00efve subjects","volume":"13","author":"SG Parisi","year":"2013","journal-title":"BMC Infect Dis."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"288.e5","DOI":"10.1016\/j.cmi.2014.10.009","article-title":"Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of na\u00efve patients with more than 4 years of effective antiretroviral therapy","volume":"21","author":"SG Parisi","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1128\/JCM.43.12.6183-6185.2005","article-title":"Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy","volume":"43","author":"L Sarmati","year":"2005","journal-title":"J Clin Microbiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1086\/587660","article-title":"The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen","volume":"46","author":"L Waters","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hiv.12389","article-title":"Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-na\u00efve patients","volume":"18","author":"V Bouteloup","year":"2017","journal-title":"HIV Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/QAD.0b013e32833e50bb","article-title":"CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression","volume":"24","author":"S Raymond","year":"2010","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T17:22:36Z","timestamp":1663089756000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213160"}},"subtitle":[],"editor":[{"given":"Nicolas","family":"Sluis-Cremer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213160","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]}}}